Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8330069 | 0.98 | MAPT (0.50) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL20334306 | 0.84 | TSHR (0.44) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL16322624 | 0.83 | KDM4E (0.50) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL31237102 | 0.83 | KDM4E (0.50) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL4898543 | 0.83 | NCF1 (0.44) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL23634035 | 0.82 | KDM4E (0.50) | MAPTKDM4ERAB9APOLBMEN1 | |
| SCHEMBL29837272 | 0.82 | KDM4E (0.50) | MAPTKDM4ERAB9APOLBMEN1 | |
| SCHEMBL3334395 | 0.82 | KDM4E (0.53) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL12173131 | 0.81 | NCF1 (0.43) | MAPTTSHRTDP1KDM4ERAB9A | |
| SCHEMBL29837257 | 0.80 | KDM4E (0.48) | MAPTKDM4ERAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-4045506-B1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-07-23 | — | — | EP | disclosed |
| CN-114502555-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridin-3-yl) pyrimidin-2-amine for the treatment of proliferative diseases and disorders | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| US-20240158391-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-05-16 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4045506-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | Aucentra Therapeutics Pty Ltd (AU) | 2022-08-24 | — | — | EP | disclosed |
| CN-114901362-A | Bivalent LECA inhibitors against pseudomonas aeruginosa biofilm formation | 赫姆霍尔兹传染病研究中心有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-1999010347-A1 | SUBSTITUTED 4-OXO-NAPTHYRIDINE-3-CARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0705260-B1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1999-03-03 | — | — | EP | disclosed |
| US-5780482-A | TREATING RHEUMATIC DISEASES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| EP-0705260-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000511-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| US-4341769-A | VASODILATOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-07-27 | — | — | US | disclosed |
| EP-0038161-A1 | 2,6-Diaminonebularines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-10-21 | — | — | EP | disclosed |
| US-4004011-A | PROLACTIN SECRETION INHIBITORS | SANDOZ LTD. (CH) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | MAPT 2486/4885TSHR 252/4885TDP1 2846/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | MAPT 2486/4885TSHR 252/4885TDP1 2846/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | MAPT 107/4885TSHR 4429/4885TDP1 1670/4885 |
| US-20240158391-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | CDK9, CDK4, CDK2 | MAPT 3759/4885TSHR 1083/4885TDP1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.